Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Stopped Slow recruitment rate into this study with rare tumors of neuroendocrine origin (enrollment issues)

Conditions

• Pancreatic Neoplasm
• Pituitary Neoplasm
• Nelson Syndrome
• Ectopic ACTH Syndrome

Interventions

• DRUG: pasireotide LAR

Sponsor

Novartis Pharmaceuticals